The Effects of Postoperative Trimetazidine Treatment on Ischemia-Reperfusion Injury after Isolated Surgical Myocardial Revascularization

1. Naviaux RK. Metabolic features and regulation of the healing cycle—A new model for chronic disease pathogenesis and treatment. Mitochondrion. 2018;46:278–297. doi: 10.1016/j.mito.2018.08.001 NaviauxRK Metabolic features and regulation of the healing cycle—A new model for chronic disease pathogenesis and treatment Mitochondrion 2018 46 278 297 10.1016/j.mito.2018.08.001 Open DOISearch in Google Scholar

2. Ballinger SW, Patterson C, Knight-Lozano CA, et al. Mitochondrial Integrity and Function in Atherogenesis. Circulation. 2002;106:544–549. doi: 10.1161/01.cir.0000023921.93743.89 BallingerSW PattersonC Knight-LozanoCA Mitochondrial Integrity and Function in Atherogenesis Circulation 2002 106 544 549 10.1161/01.cir.0000023921.93743.89 Open DOISearch in Google Scholar

3. Wallace DC. Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science. 1992;256:628–632. doi: 10.1126/science.1533953 WallaceDC Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science 1992 256 628 632 10.1126/science.1533953 Open DOISearch in Google Scholar

4. Yu E, Calvert PA, Mercer JR, et al. Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans. Circulation. 2013;128:702–712. doi: 10.1161/CIRCULATIONAHA.113.002271 YuE CalvertPA MercerJR Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans Circulation 2013 128 702 712 10.1161/CIRCULATIONAHA.113.002271 Open DOISearch in Google Scholar

5. Zweier JL, Talukder MA. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res. 2006;70(2):181–190. doi: 10.1016/j.cardiores.2006.02.025 ZweierJL TalukderMA The role of oxidants and free radicals in reperfusion injury Cardiovasc Res 2006 70 2 181 190 10.1016/j.cardiores.2006.02.025 Open DOISearch in Google Scholar

6. Dhalla NS, Elmoselhi AB, Hata T, Makino N. Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res. 2000;47(3):446–56. doi: 10.1016/s0008-6363(00)00078-x DhallaNS ElmoselhiAB HataT MakinoN Status of myocardial antioxidants in ischemia-reperfusion injury Cardiovasc Res 2000 47 3 446 56 10.1016/s0008-6363(00)00078-x Open DOISearch in Google Scholar

7. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013;123(1):92–100. doi: 10.1172/JCI62874 HausenloyDJ YellonDM Myocardial ischemia-reperfusion injury: a neglected therapeutic target J Clin Invest 2013 123 1 92 100 10.1172/JCI62874 Open DOISearch in Google Scholar

8. Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res. 1998;38(2):291–300. doi: 10.1016/s0008-6363(98)00033-9 PiperHM Garcia-DoradoD OvizeM A fresh look at reperfusion injury Cardiovasc Res 1998 38 2 291 300 10.1016/s0008-6363(98)00033-9 Open DOISearch in Google Scholar

9. Cameron AA, Davis KB, Rogers WJ. Recurrence of angina after coronary artery bypass surgery: predictors and prognosis (CASS Registry). Coronary Artery Surgery Study. J Am Coll Cardiol. 1995 Oct;26(4):895–899. doi: 10.1016/0735-1097(95)00280-4 CameronAA DavisKB RogersWJ Recurrence of angina after coronary artery bypass surgery: predictors and prognosis (CASS Registry). Coronary Artery Surgery Study J Am Coll Cardiol 1995 Oct 26 4 895 899 10.1016/0735-1097(95)00280-4 Open DOISearch in Google Scholar

10. Pocock SJ, Henderson RA, Seed P, et al. Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) Trial. Circulation. 1996;94:135–142. doi: 10.1161/01.cir.94.2.135 PocockSJ HendersonRA SeedP Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) Trial Circulation 1996 94 135 142 10.1161/01.cir.94.2.135 Open DOISearch in Google Scholar

11. Boden WE, O’rourke RA, Teo KK, et al.; COURAGE trial coprincipal investigators and study coordinators. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE trial). Am Heart J. 2006;151:1173–1179. doi: 10.1016/j.ahj.2005.08.015 BodenWE O’rourkeRA TeoKK COURAGE trial coprincipal investigators and study coordinators Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE trial) Am Heart J 2006 151 1173 1179 10.1016/j.ahj.2005.08.015 Open DOISearch in Google Scholar

12. Task Force Members; Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003. doi: 10.1093/eurheartj/eht296 Task Force Members MontalescotG SechtemU AchenbachS 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology Eur Heart J 2013 34 38 2949 3003 10.1093/eurheartj/eht296 Open DOISearch in Google Scholar

13. Lisboa da Silva RMF. Additional and emerging drugs for standard therapy for patients with stable angina. E-Journal of Cardiology Practice. 2017;15(11). Lisboa da SilvaRMF Additional and emerging drugs for standard therapy for patients with stable angina E-Journal of Cardiology Practice 2017 15 11 Search in Google Scholar

14. Kallistratos MS, Poulimenos LE, Manolis AJ. Stable angina pectoris: which drugs or combinations to use in which patients. E-Journal of Cardiology Practice. 2017;15(8). KallistratosMS PoulimenosLE ManolisAJ Stable angina pectoris: which drugs or combinations to use in which patients E-Journal of Cardiology Practice 2017 15 8 Search in Google Scholar

15. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86:580–588. doi: 10.1161/01.res.86.5.580 KantorPF LucienA KozakR LopaschukGD The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase Circ Res 2000 86 580 588 10.1161/01.res.86.5.580 Open DOISearch in Google Scholar

16. Di Napoli P, Chierchia S, Taccardi AA, et al. Trimetazidine improves postischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric Oxide. 2007;16:228–236. doi: 10.1016/j.niox.2006.09.001 Di NapoliP ChierchiaS TaccardiAA Trimetazidine improves postischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts Nitric Oxide 2007 16 228 236 10.1016/j.niox.2006.09.001 Open DOISearch in Google Scholar

17. Fragasso G, Piatti Md PM, Monti L, et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003;146(5):E18. doi: 10.1016/S0002-8703(03)00415-0 FragassoG Piatti MdPM MontiL Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy Am Heart J 2003 146 5 E18 10.1016/S0002-8703(03)00415-0 Open DOISearch in Google Scholar